614 results on '"Schwabe, Robert F."'
Search Results
202. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis.
- Author
-
Affò, Silvia, Dominguez, Marlene, Lozano, Juan José, Sancho-Bru, Pau, Rodrigo-Torres, Daniel, Morales-Ibanez, Oriol, Moreno, Montserrat, Millán, Cristina, Loaeza-del-Castillo, Aurora, Altamirano, José, García-Pagán, Juan Carlos, Arroyo, Vicente, Ginès, Pere, Caballería, Juan, Schwabe, Robert F., and Bataller, Ramon
- Subjects
TRANSCRIPTION factors ,TUMOR necrosis factors ,DRUG synergism ,PROTEIN receptors ,HEPATITIS treatment ,ALCOHOLISM ,TARGETED drug delivery ,ANIMAL models in research - Abstract
Objective Alcoholic hepatitis (AH) is a severe clinical condition that needs novel therapies. The identification of targets for therapy is hampered by the lack of animal models of advanced AH. The authors performed a translational study through a transcriptome analysis in patients with AH to identify new molecular targets. Design Hepatic gene expression profiling was assessed by DNA microarray in patients with AH (n=15) and normal livers (n=7). Functional analysis was assessed by gene set enrichment analysis. Quantitative PCR was performed in patients with AH (n=40), hepatitis C (n=18), non-alcoholic steatohepatitis (n=20) and in mouse models of acute and chronic liver injury. Protein expression was assessed by immunohistochemistry and western blotting. Results Gene expression analysis showed 207 genes >5-fold differentially expressed in patients with AH and revealed seven pathways differentially regulated including 'cytokineecytokine receptor interaction'. Several tumour necrosis factor (TNF) superfamily receptors, but not ligands, were overexpressed in AH. Importantly, Fn14 was the only TNF superfamily receptor exclusively upregulated in AH compared with other liver diseases and correlated with both 90-day mortality and severity of portal hypertension. Fn14 protein expression was detected in areas of fibrogenesis and in a population of hepatocytes. Fn14 expression was increased in experimental models of liver injury and was detected in progenitor cells. Conclusion Translational research revealed that TNF superfamily receptors are overexpressed in AH. Fn14, the receptor for TNF-like weak inducer of apoptosis, is selectively upregulated in patients with AH. TNF superfamily receptors could represent a potential target for therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
203. Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition.
- Author
-
Kluwe, Johannes, Pradere, Jean–Philippe, Gwak, Geum–Youn, Mencin, Ali, De Minicis, Samuele, Österreicher, Christoph H., Colmenero, Jordi, Bataller, Ramon, and Schwabe, Robert F.
- Subjects
FIBROSIS ,ENZYME inhibitors ,ENZYME activation ,LIVER injuries ,IMMUNOFLUORESCENCE ,TRANSFORMING growth factors ,LABORATORY mice ,GREEN fluorescent protein ,PLATELET-derived growth factor - Abstract
Background & Aims: c-Jun N-terminal kinase (JNK) is activated by multiple profibrogenic mediators; JNK activation occurs during toxic, metabolic, and autoimmune liver injury. However, its role in hepatic fibrogenesis is unknown. Methods: JNK phosphorylation was detected by immunoblot analysis and confocal immunofluorescent microscopy in fibrotic livers from mice after bile duct ligation (BDL) or CCl
4 administration and in liver samples from patients with chronic hepatitis C and non-alcoholic steatohepatitis. Fibrogenesis was investigated in mice given the JNK inhibitor SP600125 and in JNK1- and JNK2-deficient mice following BDL or CCl4 administration. Hepatic stellate cell (HSC) activation was determined in primary mouse HSCs incubated with pan-JNK inhibitors SP600125 and VIII. Results: JNK phosphorylation was strongly increased in livers of mice following BDL or CCl4 administration as well as in human fibrotic livers, occurring predominantly in myofibroblasts. In vitro, pan-JNK inhibitors prevented transforming growth factor (TGF) β-, platelet-derived growth factor-, and angiotensin II-induced murine HSC activation and decreased platelet-derived growth factor and TGF-β signaling in human HSCs. In vivo, pan-JNK inhibition did not affect liver injury but significantly reduced fibrosis after BDL or CCl4 . JNK1-deficient mice had decreased fibrosis after BDL or CCl4 , whereas JNK2-deficient mice displayed increased fibrosis after BDL but fibrosis was not changed after CCl4 . Moreover, patients with chronic hepatitis C who displayed decreased fibrosis in response to the angiotensin receptor type 1 blocker losartan showed decreased JNK phosphorylation. Conclusions: JNK is involved in HSC activation and fibrogenesis and represents a potential target for antifibrotic treatment approaches. [Copyright &y& Elsevier]- Published
- 2010
- Full Text
- View/download PDF
204. Toll-like receptors, wound healing, and carcinogenesis.
- Author
-
Kluwe, Johannes, Mencin, Ali, and Schwabe, Robert F.
- Subjects
CELLS ,EXTRACELLULAR matrix ,CARCINOGENESIS ,WOUND healing ,FIBROSIS ,CANCER - Abstract
Following acute injury, the concerted action of resident and nonresident cell populations evokes wound healing responses that entail a temporary increase in inflammation, extracellular matrix production, and proliferation to ultimately restore normal organ architecture. However, chronic injury evokes a perpetuating wound healing response promoting the development of fibrosis, organ failure, and cancer. Recent evidence points toward toll-like receptors (TLRs) as important regulators of inflammatory signals in wound healing. Here, we will review the activation of TLRs by different endogenous and bacterial TLR ligands during wound healing, and the contribution of TLR-induced signals to injury, fibrogenesis, regeneration, and carcinogenesis. We will discuss the hypothesis that TLRs act as sensors of danger signals in injured tissue to switch the wound healing response toward fibrogenesis and regeneration as a protective response to imminent danger at the cost of an increased long-term risk of developing scars and cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
205. Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis.
- Author
-
Siegmund, Sören V. and Schwabe, Robert F.
- Subjects
- *
LIVER diseases , *FIBROSIS , *HYPERTENSION , *LIVER cells , *CANNABINOIDS - Abstract
Siegmund SV, Schwabe RF. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol 294: G357-G362, 2008. First published November 15, 2007; doi: 10.11 52/ajpgi.00456.2007.—Hepatic fibrosis is the response of the liver to chronic injury and is associated with portal hypertension, progression to hepatic cirrhosis, liver failure, and high incidence of hepatocellular carcinoma. On a molecular level, a large number of signaling pathways have been shown to contribute to the activation of fibrogenic cell types and the subsequent accumulation of extracellular matrix in the liver. Recent evidence suggests that the endocannabinoid system is an important part of this complex signaling network. In the injured liver, the endocannabinoid system is upregulated both at the level of endocannabinoids and at the endocannabinoid receptors CB1 and CB2. The hepatic endocannabinoid system mediates both pro- and antifibrogenic effects by activating distinct signaling pathways that differentially affect proliferation and death of fibrogenic cell types. Here we will summarize current findings on the role of the hepatic endocannabinoid system in liver fibrosis and discuss emerging options for its therapeutic exploitation. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
206. Free Cholesterol-loaded Macrophages Are an Abundant Source of Tumor Necrosis Factor-α and Interleukin-6.
- Author
-
Yankun Li, Schwabe, Robert F., DeVries-Seimon, Tracie, Pin Mei Yao, Gerbod-Giannone, Marie-Christine, Tall, Alan R., Davis, Roger J., Flavell, Richard, Brenner, David A., and Tabas, Ira
- Subjects
- *
MACROPHAGES , *TUMOR necrosis factors , *INTERLEUKIN-6 , *MESSENGER RNA , *CYTOKINES , *ENDOPLASMIC reticulum , *ORGANELLES , *BIOCHEMISTRY - Abstract
Two key features of atherosclerotic plaques that precipitate acute atherothrombotic vascular occlusion (‘vulnerable plaques’) are abundant inflammatory mediators and macrophages with excess unesterified, or ‘free,’ cholesterol (FC). Herein we show that FC accumulation in macrophages leads to the induction and secretion of two inflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). The increases in TNF-α and IL-6 mRNA and protein were mediated by FC-induced activation of the IκB kinase/ NF-κB pathway as well as activation of MKK3/p38, Erk1/2, and JNK1/2 mitogen-activated protein kinases (MAPK). Activation of IκB kinase and JNK1/2 was needed for the induction of both cytokines. However, MKK3/p38 signaling was specifically involved in TNF-α induction, and Erk1/2 signaling was required for IL-6. Most interestingly, activation of all of the signaling pathways and induction of both cytokines required cholesterol trafficking to the endoplasmic reticulum (ER). The CHOP branch of the unfolded protein response, an ER stress pathway, was required for Erk1/2 activation and IL-6 induction. In contrast, one or more other ER-related pathways were responsible for activation of p38, JNK1/2, and IκB kinase/NF-κB and for the induction of TNF-α. These data suggest a novel scenario in which cytokines are induced in macrophages by endogenous cellular events triggered by excess ER cholesterol rather than by exogenous immune cell mediators. Moreover, this model may help explain the relationship between FC accumulation and inflammation in vulnerable plaques. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
207. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration.
- Author
-
Schwabe, Robert F., Bataller, Ramón, and Brenner, David A.
- Subjects
- *
KUPFFER cells , *CELLULAR signal transduction - Abstract
Activated hepatic stellate cells (HSCs) are the main producers of extracellular matrix in the fibrotic liver and are involved in the regulation of hepatic inflammation. The aim of this study was to characterize the role of regulated on activation, normal T-cell expressed, and presumably secreted (RANTES) in activated HSCs. RANTES mRNA and protein secretion were strongly induced after stimulating HSCs with TNF-α, IL-1β, or CD40L. RANTES production was NF-κB dependent, because inhibitor-κB (IκB) superrepressor and dominant-negative IκB kinase-2 almost completely blocked RANTES expression. NF-κB activation was sufficient to drive RANTES expression as demonstrated by the strong induction of RANTES in HSCs expressing NF-κB-inducing kinase. The JNK/ activator protein-1 pathway also contributed to RANTES expression as demonstrated by the blocking effects of the JNK inhibitor SP600125. HSCs responded to stimulation with recombinant human (rh)RANTES with an increase in intracellular calcium concentration and a rapid increase in free radical formation. Furthermore, rhRANTES induced ERK phosphorylation, ERK-dependent [³H]thymidine incorporation, and HSC proliferation. Additionally, rhRANTES induced focal adhesion kinase phosphorylation and a substantial increase in HSC migration. HSCs functionally expressed chemokine receptor-5 (CCR5), as shown by flow cytometric analysis and RT-PCR, and the inhibitory effects of a blocking CCR5 antibody on rhRANTES-induced ERK activation, proliferation, and migration. Diphenylene iodonium and N-acetylcysteine inhibited rhRANTES-induced ERK activation and HSC proliferation, indicating that NADPH oxidase-dependent production of reactive oxygen species was required. In conclusion, RANTES and CCR5 represent potential mediators of 1) HSC migration and proliferation and 2) a cross-talk between HSCs and leukocytes during fibrogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
208. Toll-Like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.
- Author
-
Paik, Yong-Han, Schwabe, Robert F., Bataller, Ramón, Russo, Maria P., Jobin, Christian, and Brenner, David A.
- Published
- 2003
- Full Text
- View/download PDF
209. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration.
- Author
-
Schwabe, Robert F., Bradham, Cynthia A., Uehara, Tetsuya, Hatano, Etsuro, Bennett, Brydon L., Schoonhoven, Robert, and Brenner, David A.
- Published
- 2003
- Full Text
- View/download PDF
210. Role of glycogen synthase kinase-3 in TNF-α-induced NF-κ B activation and apoptosis in hepatocytes.
- Author
-
Schwabe, Robert F. and Brenner, David A.
- Subjects
- *
GLYCOGEN , *TUMOR necrosis factors , *APOPTOSIS , *LIVER cells , *THERAPEUTICS - Abstract
Discusses a study which assessed the role of Glycogen Synthase Kinase-3 in the regulation of Tumor Necrosis Factor-α-induced Necrosis Factor-κ Β activation in hepatocytes. Background on hepatocyte isolation and culture; Detection of apoptosis; Information on immunofluorescent staining.
- Published
- 2002
- Full Text
- View/download PDF
211. Differential role of IκB kinase 1 and 2 in primary rat hepatocytes.
- Author
-
Schwabe, Robert F., Bennett, Brydon L., Manning, Anthony M., and Brenner, David A.
- Published
- 2001
- Full Text
- View/download PDF
212. Gut microbiota and Toll-like receptors set the stage for cytokine-mediated failure of antibacterial responses in the fibrotic liver
- Author
-
Kuntzen, Christian and Schwabe, Robert F
- Published
- 2017
- Full Text
- View/download PDF
213. The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver
- Author
-
Mederacke, Ingmar, Filliol, Aveline, Affo, Silvia, Nair, Ajay, Hernandez, Celine, Sun, Qiuyan, Hamberger, Florian, Brundu, Francesco, Chen, Yu, Ravichandra, Aashreya, Huebener, Peter, Anke, Helena, Shi, Hongxue, Martínez García de la Torre, Raquel A., Smith, James R., Henderson, Neil C., Vondran, Florian W. R., Rothlin, Carla V., Baehre, Heike, Tabas, Ira, Sancho-Bru, Pau, and Schwabe, Robert F.
- Abstract
Fibrosis contributes to ~45% of deaths in western countries. In chronic liver disease, fibrosis is a major factor determining outcomes, but efficient antifibrotic therapies are lacking. Although platelet-derived growth factor and transforming growth factor–β constitute key fibrogenic mediators, they do not account for the well-established link between cell death and fibrosis in the liver. Here, we hypothesized that damage-associated molecular patterns (DAMPs) may link epithelial cell death to fibrogenesis in the injured liver. DAMP receptor screening identified purinergic receptor P2Y14 among several candidates as highly enriched in hepatic stellate cells (HSCs), the main fibrogenic cell type of the liver. Conversely, P2Y14 ligands uridine 5′-diphosphate (UDP)–glucose and UDP-galactose were enriched in hepatocytes and were released upon different modes of cell death. Accordingly, ligand-receptor interaction analysis that combined proteomic and single-cell RNA sequencing data revealed P2Y14 ligands and P2Y14 receptor as a link between dying cells and HSCs, respectively. Treatment with P2Y14 ligands or coculture with dying hepatocytes promoted HSC activation in a P2Y14-dependent manner. P2Y14 ligands activated extracellular signal–regulated kinase (ERK) and Yes-associated protein (YAP) signaling in HSCs, resulting in ERK-dependent HSC activation. Global and HSC-selective P2Y14 deficiency attenuated liver fibrosis in multiple mouse models of liver injury. Functional expression of P2Y14 was confirmed in healthy and diseased human liver and human HSCs. In conclusion, P2Y14 ligands and their receptor constitute a profibrogenic DAMP pathway that directly links cell death to fibrogenesis.
- Published
- 2022
- Full Text
- View/download PDF
214. Author Correction: A molecular single-cell lung atlas of lethal COVID-19
- Author
-
Melms, Johannes C., Biermann, Jana, Huang, Huachao, Wang, Yiping, Nair, Ajay, Tagore, Somnath, Katsyv, Igor, Rendeiro, André F., Amin, Amit Dipak, Schapiro, Denis, Frangieh, Chris J., Luoma, Adrienne M., Filliol, Aveline, Fang, Yinshan, Ravichandran, Hiranmayi, Clausi, Mariano G., Alba, George A., Rogava, Meri, Chen, Sean W., Ho, Patricia, Montoro, Daniel T., Kornberg, Adam E., Han, Arnold S., Bakhoum, Mathieu F., Anandasabapathy, Niroshana, Suárez-Fariñas, Mayte, Bakhoum, Samuel F., Bram, Yaron, Borczuk, Alain, Guo, Xinzheng V., Lefkowitch, Jay H., Marboe, Charles, Lagana, Stephen M., Del Portillo, Armando, Tsai, Emily J., Zorn, Emmanuel, Markowitz, Glen S., Schwabe, Robert F., Schwartz, Robert E., Elemento, Olivier, Saqi, Anjali, Hibshoosh, Hanina, Que, Jianwen, and Izar, Benjamin
- Published
- 2021
- Full Text
- View/download PDF
215. List of Contributors
- Author
-
Apte, Minoti V., Hasegawa, Daisuke, Wallace, Michael C., Friedman, Scott L., Brenner, David A., Caligiuri, Alessandra, Campana, Lara, Dapito, Dianne H., Gandhi, Chandrashekhar R., Iredale, John, Kawada, Norifumi, Kisseleva, Tatiana, Koyama, Yukinori, Lotersztajn, Sophie, Mallat, Ariane, Mandal, Palash, Mann, Derek A., Marra, Fabio, Nagy, Laura E., Oakley, Fiona, Parola, Maurizio, Pinzani, Massimo, Pirola, Romano C., Rockey, Don C., Rombouts, Krista, Schwabe, Robert F., Wang, Ping, and Wilson, Jeremy S.
- Published
- 2015
- Full Text
- View/download PDF
216. Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis.
- Author
-
Wang, Xiaobo, Cai, Bishuang, Yang, Xiaoming, Sonubi, Oluwatoni O., Zheng, Ze, Ramakrishnan, Rajasekhar, Shi, Hongxue, Valenti, Luca, Pajvani, Utpal B., Sandhu, Jaspreet, Infante, Rodney E., Radhakrishnan, Arun, Covey, Douglas F., Guan, Kun-Liang, Buck, Jochen, Levin, Lonny R., Tontonoz, Peter, Schwabe, Robert F., and Tabas, Ira
- Abstract
Incomplete understanding of how hepatosteatosis transitions to fibrotic non-alcoholic steatohepatitis (NASH) has limited therapeutic options. Two molecules that are elevated in hepatocytes in human NASH liver are cholesterol, whose mechanistic link to NASH remains incompletely understood, and TAZ, a transcriptional regulator that promotes fibrosis but whose mechanism of increase in NASH is unknown. We now show that increased hepatocyte cholesterol upregulates TAZ and promotes fibrotic NASH. ASTER-B/C-mediated internalization of plasma membrane cholesterol activates soluble adenylyl cyclase (sAC; ADCY10), triggering a calcium-RhoA-mediated pathway that suppresses β-TrCP/proteasome-mediated TAZ degradation. In mice fed with a cholesterol-rich NASH-inducing diet, hepatocyte-specific silencing of ASTER-B/C, sAC, or RhoA decreased TAZ and ameliorated fibrotic NASH. The cholesterol-TAZ pathway is present in primary human hepatocytes, and associations among liver cholesterol, TAZ, and RhoA in human NASH liver are consistent with the pathway. Thus, hepatocyte cholesterol contributes to fibrotic NASH by increasing TAZ, suggesting new targets for therapeutic intervention. • Liver cholesterol and TAZ are elevated in human and mouse fibrotic NASH • Increased hepatocyte cholesterol upregulates TAZ in human and mouse hepatocytes • Cholesterol blocks TAZ proteasomal degradation via an adenylyl cyclase-RhoA pathway • Silencing the pathway in hepatocytes lowers TAZ and fibrosis in experimental NASH Cholesterol is consistently elevated in human NASH, but its mechanistic link to NASH progression remains incompletely understood. Wang et al. now define a cholesterol-TAZ connection, in which increased hepatocyte cholesterol upregulates TAZ through an adenylyl cyclase-calcium-RhoA pathway and promotes fibrotic NASH. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
217. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis.
- Author
-
Cai, Bishuang, Dongiovanni, Paola, Corey, Kathleen E., Wang, Xiaobo, Shmarakov, Igor O., Zheng, Ze, Kasikara, Canan, Davra, Viralkumar, Meroni, Marica, Chung, Raymond T., Rothlin, Carla V., Schwabe, Robert F., Blaner, William S., Birge, Raymond B., Valenti, Luca, and Tabas, Ira
- Abstract
Nonalcoholic steatohepatitis (NASH) is emerging as a leading cause of chronic liver disease. However, therapeutic options are limited by incomplete understanding of the mechanisms of NASH fibrosis, which is mediated by activation of hepatic stellate cells (HSCs). In humans, human genetic studies have shown that hypomorphic variations in MERTK , encoding the macrophage c-mer tyrosine kinase (MerTK) receptor, provide protection against liver fibrosis, but the mechanisms remain unknown. We now show that holo- or myeloid-specific Mertk targeting in NASH mice decreases liver fibrosis, congruent with the human genetic data. Furthermore, ADAM metallopeptidase domain 17 (ADAM17)-mediated MerTK cleavage in liver macrophages decreases during steatosis to NASH transition, and mice with a cleavage-resistant MerTK mutant have increased NASH fibrosis. Macrophage MerTK promotes an ERK-TGFβ1 pathway that activates HSCs and induces liver fibrosis. These data provide insights into the role of liver macrophages in NASH fibrosis and provide a plausible mechanism underlying MERTK as a genetic risk factor for NASH fibrosis. • MerTK signaling in liver macrophages promotes liver fibrosis in NASH • Macrophage MerTK activates hepatic stellate cells in NASH by inducing TGF-β1 • ATRA-induced MerTK cleavage blocks the TGF-b1-fibrosis pathway in steatosis • ATRA-induced MerTK cleavage becomes defective in NASH Genome-wide association studies have indicated that MerTK is a risk factor for liver fibrosis in NASH with an unknown mechanism. Cai et al. discovered that MerTK signaling in liver macrophages, which is enhanced in NASH owing to suppression of its cleavage by ADAM17, promotes TGF-β1 production, HSC activation, and liver fibrosis in NASH. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
218. Differential requirement for c-Jun NH2-terminal kinase in TNFα- and Fas-mediated apoptosis in hepatocytes.
- Author
-
Schwabe, Robert F., Uchinami, Hiroshi, Ting Qian, Bennett, Brydon L., Lemasters, John J., and Brenner, David A.
- Subjects
- *
APOPTOSIS , *CELL death , *LIVER cells , *CELLS , *CELL receptors - Abstract
Deals with a study which analyzed how inhibition of c-Jun NH2-terminal kinase (JNK) activity affects death receptor-mediated apoptosis and at what level JNK acts in death receptor-induced apoptosis in primary hepatocytes. Effect of prolonged JNK activation on TNFα cells; Independence of Fas-induced apoptosis of hepatocytes from JNK activation.
- Published
- 2004
- Full Text
- View/download PDF
219. Animal models of HCC – When injury meets mutation.
- Author
-
Caviglia, Jorge Matias, Schwabe, Robert F., and Yan, Jun
- Subjects
- *
LIVER cancer , *CATENINS , *LIVER injuries , *CIRRHOSIS of the liver , *GENE therapy , *PROGNOSIS - Abstract
Most hepatocellular carcinomas (HCCs) develop in patients with liver cirrhosis as a consequence of long-term liver injury, and can be ascribed to one or several etiological factors including chronic viral hepatitis, alcoholic or non-alcoholic fatty liver disease or aflatoxin ingestion.2 Moreover, a wide range of mutations and signaling pathways that drive hepatocarcinogenesis have been identified, even though they vary widely between patients.3 Ideally, incorporation of etiological factors and mutations into animal models could result in a translational model resembling human HCC.
- Published
- 2018
- Full Text
- View/download PDF
220. Aryl Hydrocarbon Receptor Signaling Prevents Activation of Hepatic Stellate Cells and Liver Fibrogenesis in Mice.
- Author
-
Yan, Jiong, Tung, Hung-Chun, Li, Sihan, Niu, Yongdong, Garbacz, Wojciech G., Lu, Peipei, Bi, Yuhan, Li, Yanping, He, Jinhan, Xu, Meishu, Ren, Songrong, Monga, Satdarshan P., Schwabe, Robert F., Yang, Da, and Xie, Wen
- Abstract
The role of aryl hydrocarbon receptor (AhR) in liver fibrosis is controversial because loss and gain of AhR activity both lead to liver fibrosis. The goal of this study was to investigate how the expression of AhR by different liver cell types, hepatic stellate cells (HSCs) in particular, affects liver fibrosis in mice. We studied the effects of AhR on primary mouse and human HSCs, measuring their activation and stimulation of fibrogenesis using RNA-sequencing analysis. C57BL/6J mice were given the AhR agonists 2,3,7,8-tetrachlorodibenzo- p -dioxin (TCDD) or 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE); were given carbon tetrachloride (CCl 4); or underwent bile duct ligation. We also performed studies in mice with disruption of Ahr specifically in HSCs, hepatocytes, or Kupffer cells. Liver tissues were collected from mice and analyzed by histology, immunohistochemistry, and immunoblotting. AhR was expressed at high levels in quiescent HSCs, but the expression decreased with HSC activation. Activation of HSCs from AhR-knockout mice was accelerated compared with HSCs from wild-type mice. In contrast, TCDD or ITE inhibited spontaneous and transforming growth factor β–induced activation of HSCs. Mice with disruption of Ahr in HSCs, but not hepatocytes or Kupffer cells, developed more severe fibrosis after administration of CCl 4 or bile duct ligation. C57BL/6J mice given ITE did not develop CCl 4 -induced liver fibrosis, whereas mice without HSC AhR given ITE did develop CCl 4 -induced liver fibrosis. In studies of mouse and human HSCs, we found that AhR prevents transforming growth factor β–induced fibrogenesis by disrupting the interaction of Smad3 with β-catenin, which prevents the expression of genes that mediate fibrogenesis. In studies of human and mouse HSCs, we found that AhR prevents HSC activation and expression of genes required for liver fibrogenesis. Development of nontoxic AhR agonists or strategies to activate AhR signaling in HSCs might be developed to prevent or treat liver fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
221. Hyaluronan synthase 2–mediated hyaluronan production mediates Notch1 activation and liver fibrosis.
- Author
-
Yang, Yoon Mee, Noureddin, Mazen, Liu, Cheng, Ohashi, Koichiro, Kim, So Yeon, Ramnath, Divya, Powell, Elizabeth E., Sweet, Matthew J., Roh, Yoon Seok, Hsin, I-Fang, Deng, Nan, Liu, Zhenqiu, Liang, Jiurong, Mena, Edward, Shouhed, Daniel, Schwabe, Robert F., Jiang, Dianhua, Lu, Shelly C., Noble, Paul W., and Seki, Ekihiro
- Abstract
Hepatic stellate cells activated by hyaluronan synthase 2–mediated hyaluronan and Notch1 promote liver fibrosis, identifying a potential target. HAlting liver fibrosis: Hepatic stellate cells (HSCs) play a key role in liver fibrosis, a process marked by the deposition of extracellular matrix including the glycosaminoglycan hyaluronan (HA). Here, Yang et al. investigated the mechanisms regulating HSCs and HA deposition using patient samples and mouse models. They found that HA synthase 2 was increased in HSCs in fibrotic patient and mouse liver tissues. HA and Notch1 signaling activated HSCs in an HA synthase 2–dependent process. Inhibiting HA synthesis reduced HSC activation and progression of liver fibrosis, identifying a therapeutic target. Hyaluronan (HA), a major extracellular matrix glycosaminoglycan, is a biomarker for cirrhosis. However, little is known about the regulatory and downstream mechanisms of HA overproduction in liver fibrosis. Hepatic HA and HA synthase 2 (HAS2) expression was elevated in both human and murine liver fibrosis. HA production and liver fibrosis were reduced in mice lacking HAS2 in hepatic stellate cells (HSCs), whereas mice overexpressing HAS2 had exacerbated liver fibrosis. HAS2 was transcriptionally up-regulated by transforming growth factor–β through Wilms tumor 1 to promote fibrogenic, proliferative, and invasive properties of HSCs via CD44, Toll-like receptor 4 (TLR4), and newly identified downstream effector Notch1. Inhibition of HA synthesis by 4-methylumbelliferone reduced HSC activation and liver fibrosis in mice. Our study provides evidence that HAS2 actively synthesizes HA in HSCs and that it promotes HSC activation and liver fibrosis through Notch1. Targeted HA inhibition may have potential to be an effective therapy for liver fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
222. Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
- Author
-
Bataller, Ramon, Rabadan, Raul, Gwak, Geum Youn, Caviglia, Jorge M., Jang, Myoung Kuk, Bower, Maureen, Khiabanian, Hossein, Pradere, Jean Philippe, Friedman, Richard, Mencin, Ali, Sartor, R. Balfour, Dapito, Dianne H., Mederacke, Ingmar, Lefkowitch, Jay H., Schwabe, Robert F., and Adeyemi, Adebowale
- Subjects
digestive system diseases ,3. Good health - Abstract
Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors (TLRs) promote hepatocellular carcinoma (HCC), a long-term consequence of chronic liver injury, inflammation and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota, and TLR4 activation in non-bone marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease.
223. 1272 Serum amyloid a activates proinflammatory signaling pathways and enhances chemokine secretion in activated human hepatic stellate cells
- Author
-
Schwabe, Robert F., Bataller, Ramon, Brenner, David A., and Jijon, Humberto B.
- Published
- 2003
- Full Text
- View/download PDF
224. 658 Supression of regeneration in small-for-size liver grafts is associated with inhibition of cyclin D1 expression: Reversal by plant polyphenols
- Author
-
Zhong, Zhi, Schwabe, Robert F., Froh, Matthias, Yang, Liu, Brenner, David A., Bunzendahl, Hartwig, and LeMasters, John J.
- Published
- 2003
- Full Text
- View/download PDF
225. NAD+ Supplementation as a Novel Approach to cURIng HCC?
- Author
-
Mederacke, Ingmar and Schwabe, Robert F.
- Subjects
- *
NAD (Coenzyme) , *LIVER cancer , *PREFOLDIN , *RNA polymerases , *GENE expression , *TRYPTOPHAN - Abstract
In this issue of Cancer Cell , Tummala and colleagues demonstrate that unconventional prefoldin RPB5 interactor (URI) expression in hepatocytes leads to hepatocellular carcinoma (HCC) development by interacting with L-tryptophan/kynurenine/nicotinamide adenine dinucleotide (NAD + ) metabolism. The results suggest that supplementation of NAD + may be a prophylactic or therapeutic approach in HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
226. GARP on hepatic stellate cells is essential for the development of liver fibrosis.
- Author
-
Zhang, Xiaolong, Sharma, Pankaj, Maschmeyer, Patrick, Hu, Yu, Lou, Mumeng, Kim, Jessica, Fujii, Hodaka, Unutmaz, Derya, Schwabe, Robert F., and Winau, Florian
- Subjects
- *
HEPATIC fibrosis , *LIVER cells , *CYTOTOXIC T cells , *KILLER cells , *CELL contraction - Abstract
Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-β docking molecule. While the immune regulatory properties of GARP on blood cells have been studied, the function of GARP on tissue stromal cells remains unclear. Here, we investigate the role of GARP expressed on hepatic stellate cells (HSCs) in the development of liver fibrosis. The function of GARP on HSCs was explored in toxin-induced and metabolic liver fibrosis models, using conditional GARP-deficient mice or a newly generated inducible system for HSC-specific gene ablation. Primary mouse and human HSCs were isolated to evaluate the contribution of GARP to the activation of latent TGF-β. Moreover, cell contraction of HSCs in the context of TGF-β activation was tested in a GARP-dependent fashion. Mice lacking GARP in HSCs were protected from developing liver fibrosis. Therapeutically deleting GARP on HSCs alleviated the fibrotic process in established disease. Furthermore, natural killer T cells exacerbated hepatic fibrosis by inducing GARP expression on HSCs through IL-4 production. Mechanistically, GARP facilitated fibrogenesis by activating TGF-β and enhancing endothelin-1-mediated HSC contraction. Functional GARP was expressed on human HSCs and significantly upregulated in the livers of patients with fibrosis. Lastly, deletion of GARP on HSCs did not augment inflammation or liver damage. GARP expressed on HSCs drives the development of liver fibrosis via cell contraction-mediated activation of latent TGF-β. Considering that systemic blockade of TGF-β has major side effects, we highlight a therapeutic niche provided by GARP and surface-mediated TGF-β activation. Thus, our findings suggest an important role of GARP on HSCs as a promising target for the treatment of liver fibrosis. Liver fibrosis represents a substantial and increasing public health burden globally, for which specific treatments are not available. Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-β docking molecule. Here, we show that GARP expressed on hepatic stellate cells drives the development of liver fibrosis. Our findings suggest GARP as a novel target for the treatment of fibrotic disease. [Display omitted] • GARP on HSCs contributes to the development of liver fibrosis through TGF-β activation. • Natural killer T cells induce GARP expression on HSCs by producing IL-4. • GARP-mediated cell contraction forms a vicious cycle driving fibrogenesis. • Patients with liver fibrosis exhibit a high level of GARP expression. • Targeting GARP on HSCs provides a safe approach to control liver fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
227. Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis.
- Author
-
Steffani, Marcella, Yana Geng, Pajvani, Utpal B., and Schwabe, Robert F.
- Subjects
- *
HEPATIC fibrosis , *FATTY liver , *CELL communication , *LIVER cells , *LIVER diseases - Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly 40% of the global adult population and may progress to metabolic dysfunction-associated steatohepatitis (MASH), and MASH-associated liver fibrosis and cirrhosis. Despite numerous studies unraveling the mechanism of hepatic fibrogenesis, there are still no approved antifibrotic therapies. The development of MASLD and liver fibrosis results from complex cell-cell interactions that often initiate within hepatocytes but remain incompletely understood. In this issue of the JCI, Yan and colleagues describe an ATF3/HES1/CEBPA/OPN pathway that links hepatocyte signals to fibrogenic activation of hepatic stellate cells and may provide new perspectives on therapeutic options for MASLD-induced liver fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
228. Toll-like receptors 2/4 agonists: a potential strategy for preventing invasion and metastasis of hepatocellular carcinoma.
- Author
-
Mencin, Ali, Kluwe, Johannes, and Schwabe, Robert F.
- Subjects
LIVER cancer ,METASTASIS - Abstract
A response from the authors of the article "Toll-Like Receptors 2/4 Agonists: A Potential Strategy for Preventing Invasion and Metastasis of Hepatocellular Carcinoma" is presented.
- Published
- 2010
- Full Text
- View/download PDF
229. Breakthroughs in hepatology.
- Author
-
Terrault, Norah A., Dufour, Jean-François, Schwabe, Robert F., and Wong, Vincent Wai-Sun
- Subjects
- *
HEPATOLOGY - Published
- 2022
- Full Text
- View/download PDF
230. Analysis of the Role of Stellate Cell VCAM-1 in NASH Models in Mice.
- Author
-
Chung, Kyoung-Jin, Legaki, Aigli-Ioanna, Papadopoulos, Grigorios, Gercken, Bettina, Gebler, Janine, Schwabe, Robert F., Chavakis, Triantafyllos, and Chatzigeorgiou, Antonios
- Subjects
- *
VASCULAR cell adhesion molecule-1 , *NON-alcoholic fatty liver disease , *LIVER cells , *CELL adhesion molecules , *LABORATORY mice - Abstract
Non-alcoholic fatty liver disease (NAFLD) can progress to non-alcoholic steatohepatitis (NASH), characterized by inflammation and fibrosis. Fibrosis is mediated by hepatic stellate cells (HSC) and their differentiation into activated myofibroblasts; the latter process is also promoted by inflammation. Here we studied the role of the pro-inflammatory adhesion molecule vascular cell adhesion molecule-1 (VCAM-1) in HSCs in NASH. VCAM-1 expression was upregulated in the liver upon NASH induction, and VCAM-1 was found to be present on activated HSCs. We therefore utilized HSC-specific VCAM-1-deficient and appropriate control mice to explore the role of VCAM-1 on HSCs in NASH. However, HSC-specific VCAM-1-deficient mice, as compared to control mice, did not show a difference with regards to steatosis, inflammation and fibrosis in two different models of NASH. Hence, VCAM-1 on HSCs is dispensable for NASH development and progression in mice. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
231. Deactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice.
- Author
-
Troeger, Juliane S., Mederacke, Ingmar, Gwak, Geum–Youn, Dapito, Dianne H., Mu, Xueru, Hsu, Christine C., Pradere, Jean–Philippe, Friedman, Richard A., and Schwabe, Robert F.
- Subjects
KUPFFER cells ,FIBROSIS ,LABORATORY mice ,APOPTOSIS ,LIVER injuries ,POLYMERASE chain reaction ,TAMOXIFEN - Abstract
Background & Aims: Activated hepatic stellate cells (HSCs), the main fibrogenic cell type in the liver, undergo apoptosis after cessation of liver injury, which contributes to resolution of fibrosis. In this study, we investigated whether HSC deactivation constitutes an additional mechanism of liver fibrosis resolution. Methods: HSC activation and deactivation were investigated by single-cell PCR and genetic tracking in transgenic mice that expressed a tamoxifen-inducible CreER under control of the endogenous vimentin promoter (Vimentin-CreER). Results: Single-cell quantitative polymerase chain reaction demonstrated activation of almost the entire HSC population in fibrotic livers, and a gradual decrease of HSC activation during fibrosis resolution, indicating deactivation of HSCs. Vimentin-CreER marked activated HSCs, demonstrated by a 6- to 16-fold induction of a membrane-bound green fluorescent protein (mGFP) Cre-reporter after injection of carbon tetrachloride, in liver and isolated HSCs, and a shift in localization of mGFP-marked HSCs from peri-sinusoidal to fibrotic septa. Tracking of mGFP-positive HSCs revealed the persistence of 40%–45% of mGFP expression in livers and isolated HSCs 30–45 days after carbon tetrachloride was no longer administered, despite normalization of fibrogenesis parameters; these findings confirm reversal of HSC activation. After fibrosis resolution, mGFP expression was observed again in desmin-positive peri-sinusoidal HSCs; no mGFP expression was detected in hepatocytes or cholangiocytes, excluding mesenchymal-epithelial transition. Notably, reverted HSCs remained in a primed state, with higher levels of responsiveness to fibrogenic stimuli. Conclusions: In mice, reversal of HSC activation contributes to termination of fibrogenesis during fibrosis resolution, but results in higher responsiveness of reverted HSCs to recurring fibrogenic stimulation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
232. Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH).
- Author
-
Jiménez, César, Ventura‐Cots, Meritxell, Sala, Margarita, Calafat, Margalida, Garcia‐Retortillo, Montserrat, Cirera, Isabel, Cañete, Nuria, Soriano, Germán, Poca, María, Simón‐Talero, Macarena, Altamirano, José, Lucey, Michael, Garcia‐Tsao, Guadalupe, Brown, Robert S., Schwabe, Robert F., Verna, Elizabeth C., Schnabl, Bernd, Bosques‐Padilla, Francisco, Mathurin, Philippe, and Caballería, Juan
- Subjects
- *
RIFAXIMIN , *LIVER failure , *HEPATITIS , *PILOT projects , *LIVER function tests - Abstract
Background & Aims: Alcoholic hepatitis (AH) is associated with a high incidence of infection and mortality. Rifaximin reduces bacterial overgrowth and translocation. We aimed to study whether the administration of rifaximin as an adjuvant treatment to corticosteroids decreases the number of bacterial infections at 90 days in patients with severe AH compared to a control cohort. Methods: This was a multicentre, open, comparative pilot study of the addition of rifaximin (1200 mg/day/90 days) to the standard treatment for severe AH. The results were compared with a carefully matched historical cohort of patients treated with standard therapy and matching by age and model of end‐stage liver disease (MELD). We evaluated bacterial infections, liver‐related complications, mortality and liver function tests after 90 days. Results: Twenty‐one and 42 patients were included in the rifaximin and control groups respectively. No significant baseline differences were found between groups. The mean number of infections per patient was 0.29 and 0.62 in the rifaximin and control groups, respectively (p =.049), with a lower incidence of acute‐on‐chronic liver failure (ACLF) linked to infections within the treatment group. Liver‐related complications were lower within the rifaximin group (0.43 vs. 1.26 complications/patient respectively) (p =.01). Mortality was lower in the treated versus the control groups (14.2% vs. 30.9, p =.15) without significant differences. No serious adverse events were associated with rifaximin treatment. Conclusions: Rifaximin is safe in severe AH with a significant reduction in clinical complications. A lower number of infections and a trend towards a lower ACLF and mortality favours its use in these patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
233. OS-026-YI Functional role of CD44+ cancer stem cells in intrahepatic cholangiocarcinoma.
- Author
-
Vilà, Paula Cantallops, Viñas, Laura Sererols, Vicién, Gemma Garcia, Ariño, Silvia, Giráldez, Carmen Cárcamo, Zanatto, Laura, de la Torre, Raquel A Martínez-García, Chen, Li, Castellano, Giancarlo, Martin, Miguel Torres, Schwabe, Robert F., Sia, Daniela, Sancho-Bru, Pau, and Affo, Silvia
- Published
- 2024
- Full Text
- View/download PDF
234. Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
- Author
-
Garrido, Amanda, Kim, Eunjeong, Teijeiro, Ana, Sánchez Sánchez, Paula, Gallo, Rosa, Nair, Ajay, Matamala Montoya, María, Perna, Cristian, Vicent, Guillermo P., Muñoz, Javier, Campos-Olivas, Ramón, Melms, Johannes C., Izar, Benjamin, Schwabe, Robert F., and Djouder, Nabil
- Subjects
- *
HISTONE acetylation , *BILE acids , *FARNESOID X receptor , *CIRRHOSIS of the liver , *HUMAN cell culture , *DEOXYCHOLIC acid , *VENOUS pressure - Abstract
Owing to the lack of genetic animal models that adequately recreate key clinical characteristics of cirrhosis, the molecular pathogenesis of cirrhosis has been poorly characterized, and treatments remain limited. Hence, we aimed to better elucidate the pathological mechanisms of cirrhosis using a novel murine model. We report on the first murine genetic model mimicking human cirrhosis induced by hepatocyte-specific elimination of microspherule protein 1 (MCRS1), a member of non-specific lethal (NSL) and INO80 chromatin-modifier complexes. Using this genetic tool with other mouse models, cell culture and human samples, combined with quantitative proteomics, single nuclei/cell RNA sequencing and chromatin immunoprecipitation assays, we investigated mechanisms of cirrhosis. MCRS1 loss in mouse hepatocytes modulates the expression of bile acid (BA) transporters – with a pronounced downregulation of Na+-taurocholate cotransporting polypeptide (NTCP) – concentrating BAs in sinusoids and thereby activating hepatic stellate cells (HSCs) via the farnesoid X receptor (FXR), which is predominantly expressed in human and mouse HSCs. Consistently, re-expression of NTCP in mice reduces cirrhosis, and genetic ablation of FXR in HSCs suppresses fibrotic marks in mice and in vitro cell culture. Mechanistically, deletion of a putative SANT domain from MCRS1 evicts histone deacetylase 1 from its histone H3 anchoring sites, increasing histone acetylation of BA transporter genes, modulating their expression and perturbing BA flow. Accordingly, human cirrhosis displays decreased nuclear MCRS1 and NTCP expression. Our data reveal a previously unrecognized function of MCRS1 as a critical histone acetylation regulator, maintaining gene expression and liver homeostasis. MCRS1 loss induces acetylation of BA transporter genes, perturbation of BA flow, and consequently, FXR activation in HSCs. This axis represents a central and universal signaling event in cirrhosis, which has significant implications for cirrhosis treatment. By genetic ablation of MCRS1 in mouse hepatocytes, we generate the first genetic mouse model of cirrhosis that recapitulates human features. Herein, we demonstrate that the activation of the bile acid/FXR axis in liver fibroblasts is key in cirrhosis development. [Display omitted] • MCRS1 loss in hepatocytes deregulates the expression of BA transporters, causing perturbation of BA flow and cirrhosis. • Re-expression of the BA transporter NTCP in MCRS1-depleted hepatocytes restores the BA flow and prevents cirrhosis. • Accumulation of BAs in liver sinusoids activates liver fibroblasts via FXR leading to fibrosis. • MCRS1 loss increases histone acetylation of BA transporter genes, altering their expression levels. • MCRS1 and NTCP expression correlates with fibrotic marks in human cirrhosis samples. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
235. TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
- Author
-
Wang, Xiaobo, Zeldin, Sharon, Shi, Hongxue, Zhu, Changyu, Saito, Yoshinobu, Corey, Kathleen E., Osganian, Stephanie A., Remotti, Helen E., Verna, Elizabeth C., Pajvani, Utpal B., Schwabe, Robert F., and Tabas, Ira
- Subjects
- *
NON-alcoholic fatty liver disease , *LIVER tumors , *FATTY liver , *DNA damage , *GENETIC models , *GENE silencing - Abstract
Non-alcoholic steatohepatitis (NASH) is a leading cause of hepatocellular carcinoma (HCC), but mechanisms linking NASH to eventual tumor formation remain poorly understood. Herein, we investigate the role of TAZ/WWTR1, which is induced in hepatocytes in NASH, in the progression of NASH to HCC. The roles of hepatocyte TAZ and its downstream targets were investigated in diet-induced and genetic models of NASH-HCC using gene-targeting, adeno-associated virus 8 (AAV8)-H1-mediated gene silencing, or AAV8-TBG-mediated gene expression. The biochemical signature of the newly elucidated pathway was probed in liver specimens from humans with NASH-HCC. When hepatocyte-TAZ was silenced in mice with pre-tumor NASH using AAV8-H1-shTaz (short-hairpin Taz), subsequent HCC tumor development was suppressed. In this setting, the tumor-suppressing effect of shTaz was not dependent of TAZ silencing in the tumors themselves and could be dissociated from the NASH-suppressing effects of shTaz. The mechanism linking pre-tumor hepatocyte-TAZ to eventual tumor formation involved TAZ-mediated induction of the NOX2-encoding gene Cybb , which led to NADPH-mediated oxidative DNA damage. As evidence, DNA damage and tumor formation could be suppressed by treatment of pre-tumor NASH mice with AAV8-H1-shCybb; AAV8-TBG-OGG1, encoding the oxidative DNA-repair enzyme 8-oxoguanine glycosylase; or AAV8-TBG-NHEJ1, encoding the dsDNA repair enzyme non-homologous end-joining factor 1. In surrounding non-tumor tissue from human NASH-HCC livers, there were strong correlations between TAZ, NOX2, and oxidative DNA damage. TAZ in pre-tumor NASH-hepatocytes, via induction of Cybb and NOX2-mediated DNA damage, contributes to subsequent HCC tumor development. These findings illustrate how NASH provides a unique window into the early molecular events that can lead to tumor formation and suggest that NASH therapies targeting TAZ might also prevent NASH-HCC. Non-alcoholic steatohepatitis (NASH) is emerging as the leading cause of a type of liver cancer called hepatocellular carcinoma (HCC), but molecular events in pre-tumor NASH hepatocytes leading to HCC remain largely unknown. Our study shows that a protein called TAZ in pre-tumor NASH-hepatocytes promotes damage to the DNA of hepatocytes and thereby contributes to eventual HCC. This study reveals a very early event in HCC that is induced in pre-tumor NASH, and the findings suggest that NASH therapies targeting TAZ might also prevent NASH-HCC. [Display omitted] • Silencing hepatocyte TAZ in pre-tumor NASH suppresses subsequent HCC. • Cybb is the key TAZ-induced gene in NASH hepatocytes that triggers tumor formation. • Cybb encodes NOX2, which promotes HCC by inducing oxidative DNA damage. • Silencing hepatocyte Cybb in pre-tumor NASH, or blocking DNA damage, suppresses HCC. • TAZ, NOX2, oxidative DNA damage are strongly correlated in human NASH-HCC liver. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
236. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
- Author
-
Song, Xinhua, Xu, Hongwei, Wang, Pan, Wang, Jingxiao, Affo, Silvia, Wang, Haichuan, Xu, Meng, Liang, Binyong, Che, Li, Qiu, Wei, Schwabe, Robert F., Chang, Tammy T., Vogl, Marion, Pes, Giovanni M., Ribback, Silvia, Evert, Matthias, Chen, Xin, and Calvisi, Diego F.
- Subjects
- *
FOCAL adhesion kinase , *CHOLANGIOCARCINOMA , *PROTEIN-tyrosine kinases , *KNOCKOUT mice - Abstract
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that is upregulated in many tumor types and is a promising target for cancer therapy. Herein, we elucidated the functional role of FAK in intrahepatic cholangiocarcinoma (iCCA) development and progression. Expression levels and activation status of FAK were determined in human iCCA samples. The functional contribution of FAK to Akt/YAP murine iCCA initiation and progression was investigated using conditional Fak knockout mice and constitutive Cre or inducible Cre mice, respectively. The oncogenic potential of FAK was further examined via overexpression of FAK in mice. In vitro cell line studies and in vivo drug treatment were applied to address the therapeutic potential of targeting FAK for iCCA treatment. FAK was ubiquitously upregulated and activated in iCCA lesions. Ablation of FAK strongly delayed Akt/YAP -driven mouse iCCA initiation. FAK overexpression synergized with activated AKT to promote iCCA development and accelerated Akt/Jag1 -driven cholangiocarcinogenesis. Mechanistically, FAK was required for YAP(Y357) phosphorylation, supporting the role of FAK as a central YAP regulator in iCCA. Significantly, ablation of FAK after Akt/YAP -dependent iCCA formation strongly suppressed tumor progression in mice. Furthermore, a remarkable iCCA growth reduction was achieved when a FAK inhibitor and palbociclib, a CDK4/6 inhibitor, were administered simultaneously in human iCCA cell lines and Akt/YAP mice. FAK activation contributes to the initiation and progression of iCCA by inducing the YAP proto-oncogene. Targeting FAK, either alone or in combination with anti-CDK4/6 inhibitors, may be an effective strategy for iCCA treatment. We found that the protein FAK (focal adhesion kinase) is upregulated and activated in human and mouse intrahepatic cholangiocarcinoma samples. FAK promotes intrahepatic cholangiocarcinoma development, whereas deletion of FAK strongly suppresses its initiation and progression. Combined FAK and CDK4/6 inhibitor treatment had a strong anti-cancer effect in in vitro and in vivo models. This combination therapy might represent a valuable and novel treatment against human intrahepatic cholangiocarcinoma. [Display omitted] • FAK is activated in human and mouse iCCA samples. • Overexpression of FAK promotes cholangiocarcinogenesis, whereas deletion of FAK strongly suppresses iCCA initiation and progression. • FAK modulates YAP nuclear localization by phosphorylating YAP at the Y357 residue to promote iCCA development. • FAK is a potential therapeutic target for human iCCA treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
237. Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis.
- Author
-
Savage, Thomas M., Fortson, Katherine T., de los Santos-Alexis, Kenia, Oliveras-Alsina, Angelica, Rouanne, Mathieu, Rae, Sarah S., Gamarra, Jennifer R., Shayya, Hani, Kornberg, Adam, Cavero, Renzo, Li, Fangda, Han, Arnold, Haeusler, Rebecca A., Adam, Julien, Schwabe, Robert F., and Arpaia, Nicholas
- Subjects
- *
HEPATIC fibrosis , *REGULATORY T cells , *NON-alcoholic fatty liver disease , *LIVER cells , *INSULIN resistance - Abstract
Production of amphiregulin (Areg) by regulatory T (Treg) cells promotes repair after acute tissue injury. Here, we examined the function of Treg cells in non-alcoholic steatohepatitis (NASH), a setting of chronic liver injury. Areg-producing Treg cells were enriched in the livers of mice and humans with NASH. Deletion of Areg in Treg cells, but not in myeloid cells, reduced NASH-induced liver fibrosis. Chronic liver damage induced transcriptional changes associated with Treg cell activation. Mechanistically, Treg cell-derived Areg activated pro-fibrotic transcriptional programs in hepatic stellate cells via epidermal growth factor receptor (EGFR) signaling. Deletion of Areg in Treg cells protected mice from NASH-dependent glucose intolerance, which also was dependent on EGFR signaling on hepatic stellate cells. Areg from Treg cells promoted hepatocyte gluconeogenesis through hepatocyte detection of hepatic stellate cell-derived interleukin-6. Our findings reveal a maladaptive role for Treg cell-mediated tissue repair functions in chronic liver disease and link liver damage to NASH-dependent glucose intolerance. [Display omitted] • Treg cells are enriched and activated in human and mouse chronic liver disease • Treg cell-derived Areg promotes liver fibrosis and glucose intolerance • Areg from Treg cells activates hepatic stellate cells via EGFR signaling • Activated hepatic stellate cells promote hepatocyte gluconeogenesis via IL-6 Non-alcoholic fatty liver disease and its progressive form, non-alcoholic steatohepatitis (NASH), are a prevalent cause of chronic liver disease. Savage et al. demonstrate that regulatory T (Treg) cells are enriched in mouse and human NASH and find that production of the EGFR ligand amphiregulin by Treg cells promotes NASH-induced liver fibrosis and glucose intolerance through direct signaling to hepatic stellate cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
238. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
- Author
-
Zhu, Changyu, Ho, Yu-Jui, Salomao, Marcela A., Dapito, Dianne H., Bartolome, Alberto, Schwabe, Robert F., Lee, Ju-Seog, Lowe, Scott W., and Pajvani, Utpal B.
- Subjects
- *
NOTCH signaling pathway , *LIVER cancer , *FATTY liver , *LIVER diseases , *GENETIC models - Abstract
The hepatocyte Notch pathway is a pathogenic factor in non-alcoholic steatohepatitis (NASH)-associated fibrosis, but its role in hepatocellular carcinoma (HCC) is less well defined. Herein, we aimed to characterize the molecular and clinical features of Notch-active human HCC, and to investigate the mechanisms by which Notch affects NASH-driven HCC. Using a 14-gene Notch score, we stratified human HCCs from multiple comprehensively profiled datasets. We performed gene set enrichment analyses to compare Notch-active HCCs with published HCC subtype signatures. Next, we sorted Notch-active hepatocytes from Notch reporter mice for RNA sequencing and characterized Notch-active tumors in an HCC model combining a carcinogen and a NASH-inducing diet. We used genetic mouse models to manipulate hepatocyte Notch to investigate the sufficiency and necessity of Notch in NASH-driven tumorigenesis. Notch-active signatures were found in ~30% of human HCCs that transcriptionally resemble cholangiocarcinoma-like HCC, exhibiting a lack of activating CTNNB1 (β-catenin) mutations and a generally poor prognosis. Endogenous Notch activation in hepatocytes is associated with repressed β-catenin signaling and hepatic metabolic functions, in lieu of increased interactions with the extracellular matrix in NASH. Constitutive hepatocyte Notch activation is sufficient to induce β-catenin-inactive HCC in mice with NASH. Notch and β-catenin show a pattern of mutual exclusivity in carcinogen-induced HCC; in this mouse model, chronic blockade of Notch led to β-catenin-dependent tumor development. Notch activity characterizes a distinct HCC molecular subtype with unique histology and prognosis. Sustained Notch signaling in chronic liver diseases can drive tumor formation without acquiring specific genomic driver mutations. The Notch signaling pathway is known to be involved in the pathogenesis of liver fibrosis. However, its role in liver cancer has not been well defined. Herein, we show that Notch activity is increased in a subset of liver cancers and is associated with poor outcomes. We also used a mouse model to show that aberrant Notch activity can drive cancer progression in obese mice. • Notch activation induces liver fibrosis, an important niche factor for tumorigenesis. • Notch is active in 30% of human hepatocellular carcinomas and is associated with poor prognosis. • Notch-active hepatocellular carcinomas are fibrotic and have low β-catenin activity in mice and humans. • Forced hepatocyte Notch activity in mice induces diet-dependent hepatocellular carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
239. Macrophage‐derived HMGB1 is dispensable for tissue fibrogenesis.
- Author
-
Personnaz, Jean, Piccolo, Enzo, Branchereau, Maxime, Filliol, Aveline, Paccoud, Romain, Moreau, Elsa, Calise, Denis, Riant, Elodie, Gourdy, Pierre, Heymes, Christophe, Schwabe, Robert F., Dray, Cédric, Valet, Philippe, and Pradère, Jean‐Philippe
- Abstract
Alarmins and damage‐associated molecular patterns (DAMPs) are powerful inflammatory mediators, capable of initiating and maintaining sterile inflammation during acute or chronic tissue injury. Recent evidence suggests that alarmins/DAMPs may also trigger tissue regeneration and repair, suggesting a potential contribution to tissue fibrogenesis. High mobility group B1 (HMGB1), a bona fide alarmin/DAMP, may be released passively by necrotic cells or actively secreted by innate immune cells. Macrophages can release large amounts of HMGB1 and play a key role in wound healing and regeneration processes. Here, we hypothesized that macrophages may be a key source of HMGB1 and thereby contribute to wound healing and fibrogenesis. Surprisingly, cell‐specific deletion approaches, demonstrated that macrophage‐derived HMGB1 is not involved in tissue fibrogenesis in multiple organs with different underlying pathologies. Compared to control HMGB1Flox mice, mice with macrophage‐specific HMGB1 deletion (HMGB1ΔMac) do not display any modification of fibrogenesis in the liver after CCL4 or thioacetamide treatment and bile duct ligation; in the kidney following unilateral ureter obstruction; and in the heart after transverse aortic constriction. Of note, even under thermoneutral housing, known to exacerbate inflammation and fibrosis features, HMGB1ΔMac mice do not show impairment of fibrogenesis. In conclusion, our study clearly establishes that macrophage‐derived HMGB1 does not contribute to tissue repair and fibrogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
240. HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis.
- Author
-
Hernandez, Celine, Huebener, Peter, Pradere, Jean-Philippe, Antoine, Daniel J., Friedman, Richard A., and Schwabe, Robert F.
- Subjects
- *
HIGH mobility group proteins , *PROGENITOR cells , *CARCINOGENESIS , *LIVER injuries , *CELL death , *CANCER invasiveness - Abstract
Cell death is a key driver of disease progression and carcinogenesis in chronic liver disease (CLD), highlighted by the well-established clinical correlation between hepatocellular death and risk for the development of cirrhosis and hepatocellular carcinoma (HCC). Moreover, hepatocellular death is sufficient to trigger fibrosis and HCC in mice. However, the pathways through which cell death drives CLD progression remain elusive. Here, we tested the hypothesis that high-mobility group box 1 (HMGB1), a damage-associated molecular pattern (DAMP) with key roles in acute liver injury, may link cell death to injury responses and hepatocarcinogenesis in CLD. While liver-specific HMGB1 deficiency did not significantly affect chronic injury responses such as fibrosis, regeneration, and inflammation, it inhibited ductular/progenitor cell expansion and hepatocyte metaplasia. HMGB1 promoted ductular expansion independently of active secretion in a nonautonomous fashion, consistent with its role as a DAMP. Liver-specific HMGB1 deficiency reduced HCC development in 3 mouse models of chronic injury but not in a model lacking chronic liver injury. As with CLD, HMGB1 ablation reduced the expression of progenitor and oncofetal markers, a key determinant of HCC aggressiveness, in tumors. In summary, HMGB1 links hepatocyte death to ductular reaction, progenitor signature, and hepatocarcinogenesis in CLD. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
241. Serum Amyloid A Induces Inflammation, Proliferation and Cell Death in Activated Hepatic Stellate Cells.
- Author
-
Siegmund, Sören V., Schlosser, Monika, Schildberg, Frank A., Seki, Ekihiro, De Minicis, Samuele, Uchinami, Hiroshi, Kuntzen, Christian, Knolle, Percy A., Strassburg, Christian P., and Schwabe, Robert F.
- Subjects
- *
KUPFFER cells , *INFLAMMATION , *BLOOD serum analysis , *AMYLOID beta-protein , *CELL proliferation , *CELL death , *DIAGNOSIS - Abstract
Serum amyloid A (SAA) is an evolutionary highly conserved acute phase protein that is predominantly secreted by hepatocytes. However, its role in liver injury and fibrogenesis has not been elucidated so far. In this study, we determined the effects of SAA on hepatic stellate cells (HSCs), the main fibrogenic cell type of the liver. Serum amyloid A potently activated IκB kinase, c-Jun N-terminal kinase (JNK), Erk and Akt and enhanced NF-κB-dependent luciferase activity in primary human and rat HSCs. Serum amyloid A induced the transcription of MCP-1, RANTES and MMP9 in an NF-κB- and JNK-dependent manner. Blockade of NF-κB revealed cytotoxic effects of SAA in primary HSCs with signs of apoptosis such as caspase 3 and PARP cleavage and Annexin V staining. Serum amyloid A induced HSC proliferation, which depended on JNK, Erk and Akt activity. In primary hepatocytes, SAA also activated MAP kinases, but did not induce relevant cell death after NF-κB inhibition. In two models of hepatic fibrogenesis, CCl4 treatment and bile duct ligation, hepatic mRNA levels of SAA1 and SAA3 were strongly increased. In conclusion, SAA may modulate fibrogenic responses in the liver in a positive and negative fashion by inducing inflammation, proliferation and cell death in HSCs. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
242. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.
- Author
-
Fischer, Kari R., Durrans, Anna, Lee, Sharrell, Sheng, Jianting, Li, Fuhai, Wong, Stephen T. C., Choi, Hyejin, El Rayes, Tina, Ryu, Seongho, Troeger, Juliane, Schwabe, Robert F., Vahdat, Linda T., Altorki, Nasser K., Mittal, Vivek, and Gao, Dingcheng
- Subjects
- *
EPITHELIAL cells , *MESENCHYMAL stem cells , *LUNG cancer treatment , *CANCER treatment , *METASTASIS , *CANCER cells , *CYCLOPHOSPHAMIDE - Abstract
The role of epithelial-to-mesenchymal transition (EMT) in metastasis is a longstanding source of debate, largely owing to an inability to monitor transient and reversible EMT phenotypes in vivo. Here we establish an EMT lineage-tracing system to monitor this process in mice, using a mesenchymal-specific Cre-mediated fluorescent marker switch system in spontaneous breast-to-lung metastasis models. We show that within a predominantly epithelial primary tumour, a small proportion of tumour cells undergo EMT. Notably, lung metastases mainly consist of non-EMT tumour cells that maintain their epithelial phenotype. Inhibiting EMT by overexpressing the microRNA miR-200 does not affect lung metastasis development. However, EMT cells significantly contribute to recurrent lung metastasis formation after chemotherapy. These cells survived cyclophosphamide treatment owing to reduced proliferation, apoptotic tolerance and increased expression of chemoresistance-related genes. Overexpression of miR-200 abrogated this resistance. This study suggests the potential of an EMT-targeting strategy, in conjunction with conventional chemotherapies, for breast cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
243. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment.
- Author
-
Xueru Mu, Español-Suñer, Regina, Mederacke, Ingmar, Affò, Silvia, Manco, Rita, Sempoux, Christine, Lemaigre, Frédéric P., Adili, Arlind, Detian Yuan, Weber, Achim, Unger, Kristian, Heikenwälder, Mathias, Leclercq, Isabelle A., Schwabe, Robert F., Mu, Xueru, and Yuan, Detian
- Subjects
- *
PROTEIN analysis , *CARCINOGENESIS , *ALPHA fetoproteins , *ANIMAL experimentation , *BILE ducts , *CARCINOGENS , *CELL differentiation , *CELL physiology , *COMPARATIVE studies , *CYTOGENETICS , *EPITHELIAL cells , *GENES , *HYDROCARBONS , *CIRRHOSIS of the liver , *LIVER tumors , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *MICROFILAMENT proteins , *NITROSOAMINES , *PHOSPHATASES , *PRECANCEROUS conditions , *RESEARCH , *RESEARCH funding , *STEM cells , *TAMOXIFEN , *EVALUATION research , *GENE expression profiling , *PHARMACODYNAMICS - Abstract
In many organs, including the intestine and skin, cancers originate from cells of the stem or progenitor compartment. Despite its nomenclature, the cellular origin of hepatocellular carcinoma (HCC) remains elusive. In contrast to most organs, the liver lacks a defined stem cell population for organ maintenance. Previous studies suggest that both hepatocytes and facultative progenitor cells within the biliary compartment are capable of generating HCC. As HCCs with a progenitor signature carry a worse prognosis, understanding the origin of HCC is of clinical relevance. Here, we used complementary fate-tracing approaches to label the progenitor/biliary compartment and hepatocytes in murine hepatocarcinogenesis. In genotoxic and genetic models, HCCs arose exclusively from hepatocytes but never from the progenitor/biliary compartment. Cytokeratin 19-, A6- and α-fetoprotein-positive cells within tumors were hepatocyte derived. In summary, hepatocytes represent the cell of origin for HCC in mice, and a progenitor signature does not reflect progenitor origin, but dedifferentiation of hepatocyte-derived tumor cells. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
244. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis.
- Author
-
Huebener, Peter, Pradere, Jean-Philippe, Hernandez, Celine, Geum-Youn Gwak, Caviglia, Jorge Matias, Mu, Xueru, Loike, John D., Jenkins, Rosalind E., Antoine, Daniel J., and Schwabe, Robert F.
- Subjects
- *
NEUTROPHILS , *NECROSIS , *INFLAMMATION , *CELL death , *ABLATION techniques - Abstract
In contrast to microbially triggered inflammation, mechanisms promoting sterile inflammation remain poorly understood. Damage-associated molecular patterns (DAMPs) are considered key inducers of sterile inflammation following cell death, but the relative contribution of specific DAMPs, including high-mobility group box1 (HMGB1), is ill defined. Due to the postnatal lethality of Hmgb7-knockout mice, the role of HMCB1 in sterile inflammation and disease processes in vivo remains controversial. Here, using conditional ablation strategies, we have demonstrated that epithelial, but not bone marrow-derived, HMGB1 is required for sterile inflammation following injury. Epithelial HMGB1, through its receptor RAGE, triggered recruitment of neutrophils, but not macrophages, toward necrosis. In clinically relevant models of necrosis, HMGB1/RAGE-induced neutrophil recruitment mediated subsequent amplification of injury, depending on the presence of neutrophil elastase. Notably, hepatocyte-specific HMGB1 ablation resulted in 100% survival following lethal acetaminophen intoxication. In contrast to necrosis, HMGB1 ablation did not alter inflammation or mortality in response to TNF-or FAS-mediated apoptosis. In LPS-induced shock, in which HMGB1 was considered a key mediator, HMGB1 ablation did not ameliorate inflammation or lethality, despite efficient reduction of HMGB1 serum levels. Our study establishes HMGB1 as a bona fide and targetable DAMPthat selectively triggers a neutrophil-mediated injury amplification loop in the setting of necrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
245. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis.
- Author
-
Affo, Silvia, Morales-Ibanez, Oriol, Rodrigo-Torres, Daniel, Altamirano, José, Blaya, Delia, Dapito, Dianne H., Millán, Cristina, Coll, Mar, Caviglia, Jorge M., Arroyo, Vicente, Caballería, Juan, Schwabe, Robert F., Ginès, Pere, Bataller, Ramón, and Pau Sancho-Bru
- Subjects
- *
HEPATITIS , *CHEMOKINES , *PHYSIOLOGICAL effects of lipopolysaccharides , *LIVER injuries , *MACROPHAGES , *HEPATIC fibrosis , *ALCOHOLIC liver diseases , *PATIENTS - Abstract
Objective Chemokines are known to play an important role in the pathophysiology of alcoholic hepatitis (AH), a form of acute-on-chronic liver injury frequently mediated by gut derived lipopolysaccharide (LPS). In our study, we hypothesise that chemokine CCL20, one of the most upregulated chemokines in patients with AH, is implicated in the pathogenesis of AH by mediating LPS induced liver injury. Design CCL20 gene expression and serum levels and their correlation with disease severity were assessed in patients with AH. Cellular sources of CCL20 and its biological effects were evaluated in vitro and in vivo in chronic, acute and acute-on-chronic experimental models of carbon tetrachloride and LPS induced liver injury. RNA interference technology was used to knockdown CCL20 in vivo. Results CCL20 hepatic and serum levels were increased in patients with AH and correlated with the degree of fibrosis, portal hypertension, endotoxaemia, disease severity scores and short term mortality. Moreover, CCL20 expression was increased in animal models of liver injury and particularly under acute-onchronic conditions. Macrophages and hepatic stellate cells (HSCs) were identified as the main CCL20 producing cell types. Silencing CCL20 in vivo reduced LPS induced aspartate aminotransferase and lactate dehydrogenase serum levels and hepatic proinflammatory and profibrogenic genes. CCL20 induced proinflammatory and profibrogenic effects in cultured primary HSCs. Conclusions Our results suggest that CCL20 upregulation is strongly associated with LPS and may not only represent a new potential biomarker to predict outcome in patients with AH but also an important mediator linking hepatic inflammation, injury and fibrosis in AH. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
246. Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
- Author
-
Dapito, Dianne H., Mencin, Ali, Gwak, Geum-Youn, Pradere, Jean-Philippe, Jang, Myoung-Kuk, Mederacke, Ingmar, Caviglia, Jorge M., Khiabanian, Hossein, Adeyemi, Adebowale, Bataller, Ramon, Lefkowitch, Jay H., Bower, Maureen, Friedman, Richard, Sartor, R. Balfour, Rabadan, Raul, and Schwabe, Robert F.
- Subjects
- *
LIVER cancer , *TOLL-like receptors , *CHROMOSOMAL translocation , *CARCINOGENESIS , *GUT microbiome , *INFLAMMATION , *TARGETED drug delivery , *APOPTOSIS , *CANCER cell proliferation , *GENE expression - Abstract
Summary: Increased translocation of intestinal bacteria is a hallmark of chronic liver disease and contributes to hepatic inflammation and fibrosis. Here we tested the hypothesis that the intestinal microbiota and Toll-like receptors (TLRs) promote hepatocellular carcinoma (HCC), a long-term consequence of chronic liver injury, inflammation, and fibrosis. Hepatocarcinogenesis in chronically injured livers depended on the intestinal microbiota and TLR4 activation in non-bone-marrow-derived resident liver cells. TLR4 and the intestinal microbiota were not required for HCC initiation but for HCC promotion, mediating increased proliferation, expression of the hepatomitogen epiregulin, and prevention of apoptosis. Gut sterilization restricted to late stages of hepatocarcinogenesis reduced HCC, suggesting that the intestinal microbiota and TLR4 represent therapeutic targets for HCC prevention in advanced liver disease. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
247. CCR1 and CCR5 promote hepatic fibrosis in mice.
- Author
-
Seki, Ekihiro, de Minicis, Samuele, Geum-Youn Gwak, Kluwe, Johannes, Inokuchi, Sayaka, Bursill, Christina A., Llovet, Josep M., Brenner, David A., Schwabe, Robert F., and Gwak, Geum-Youn
- Subjects
- *
FIBROSIS , *LIVER injuries , *INFLAMMATORY mediators , *CHEMOKINES , *MACROPHAGES , *KUPFFER cells , *CELL migration , *ANIMAL experimentation , *CELL motility , *CELL receptors , *CIRRHOSIS of the liver , *MEDICAL cooperation , *MICE , *RESEARCH , *ANTI-HIV agents , *PREVENTION , *PHYSIOLOGY , *CELL physiology - Abstract
Hepatic fibrosis develops as a response to chronic liver injury and almost exclusively occurs in a proinflammatory environment. However, the role of inflammatory mediators in fibrogenic responses of the liver is only poorly understood. We therefore investigated the role of CC chemokines and their receptors in hepatic fibrogenesis. The CC chemokines MIP-1alpha, MIP-1beta, and RANTES and their receptors CCR1 and CCR5 were strongly upregulated in 2 experimental mouse models of fibrogenesis. Neutralization of CC chemokines by the broad-spectrum CC chemokine inhibitor 35k efficiently reduced hepatic fibrosis, and CCR1- and CCR5-deficient mice displayed substantially reduced hepatic fibrosis and macrophage infiltration. Analysis of fibrogenesis in CCR1- and CCR5-chimeric mice revealed that CCR1 mediates its profibrogenic effects in BM-derived cells, whereas CCR5 mediates its profibrogenic effects in resident liver cells. CCR5 promoted hepatic stellate cell (HSC) migration through a redox-sensitive, PI3K-dependent pathway. Both CCR5-deficient HSCs and CCR1- and CCR5-deficient Kupffer cells displayed strong suppression of CC chemokine-induced migration. Finally, we detected marked upregulation of RANTES, CCR1, and CCR5 in patients with hepatic cirrhosis, confirming activation of the CC chemokine system in human fibrogenesis. Our data therefore support a role for the CC chemokine system in hepatic fibrogenesis and suggest distinct roles for CCR1 and CCR5 in Kupffer cells and HSCs. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
248. AS024 - Single cell RNA sequencing and functional in vivo genetic manipulation reveal heterogeneity and tumor-promoting roles of cancer-associated fibroblasts in intrahepatic cholangiocarcinoma.
- Author
-
Affò, Silvia, Ravichandra, Aashreya, Brundu, Francesco, Filliol, Aveline, Chin, LiKang, Wen, Wen, Yin, Deqi, Bhattacharjee, Sonakshi, Rabadan, Raul, Kalluri, Raghu, Zender, Lars, Wells, Rebecca, Chen, Xin, and Schwabe, Robert F.
- Subjects
- *
NUCLEOTIDE sequence , *NON-coding RNA , *FIBROBLASTS , *HETEROGENEITY , *CELLS - Published
- 2020
- Full Text
- View/download PDF
249. Roles for C16-ceramide and Sphingosine 1-Phosphate in Regulating Hepatocyte Apoptosis in Response to Tumor Necrosis Factor-α.
- Author
-
Osawa, Yosuke, Uchinami, Hiroshi, Bielawski, Jacek, Schwabe, Robert F., Hannun, Yusuf A., and Brenner, David A.
- Subjects
- *
CERAMIDES , *GLYCOSPHINGOLIPIDS , *GLYCOLIPIDS , *SPHINGOSINE , *LIVER cells , *APOPTOSIS , *CELL death , *TUMOR necrosis factors - Abstract
Tumor necrosis factor (TNF)-α signals cell death and simultaneously induces the generation of ceramide, which is metabolized to sphingosine and sphingosine 1-phosphate (SIP) by ceramidase (CDase) and sphingosine kinase. Because the dynamic balance between the intracellular levels of ceramide and SIP (the ‘ceramide/S1P rheostat’) may determine cell survival, we investigated these sphingolipid signaling pathways in TNF-α-induced apoptosis of primary hepatocytes. Endogenous C16-ceramide was elevated during TNF-α-induced apoptosis in both rat and mouse primary hepatocytes. The putative acid sphingomyelinase (ASMase) inhibitor imipramine inhibited TNF-α-induced apoptosis and C16-ceramide increase as did the knock out of ASMase. Overexpression of neutral CDase (NCDase) inhibited the TNF-α-induced increase of Cle-ceramide and apoptosis in rat primary hepatocytes. Moreover, NCDase inhibited liver injury and hepatocyte apoptosis in mice treated with D-galactosamine plus TNF-α. This protective effect was abrogated by the sphingosine kinase inhibitor N,N-demethylsphingosine, suggesting that the survival effect of NCDase is due to not only C16-ceramide reduction but also S1P formation. Administration of SIP or overexpression of NCDase activated the pro-survival kinase AKT, and overexpression of dominant negative AKT blocked the survival effect of NCDase. In conclusion, activation of ASMase and generation of C16-ceramide contributed to TNF-α-induced hepatocyte apoptosis. NCDase prevented apoptosis both by reducing C16-ceramide and by activation of AKT through SIP formation. Therefore, the cross-talk between sphingolipids and AKT pathway may determine hepatocyte apoptosis by TNF-α. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
250. Transforming Growth Factor-β1 Inhibits Non-pathogenic Gram-negative Bacteria-induced NF-κB Recruitment to the Interleukin-6 Gene Promoter in Intestinal Epithelial Cells through Modulation of Histone Acetylation.
- Author
-
Haller, Dirk, Holt, Lisa, Kim, Sandra C., Schwabe, Robert F., Sartor, R. Balfour, and Jobin, Christian
- Subjects
- *
TRANSFORMING growth factors-beta , *NF-kappa B , *INTERLEUKIN-6 , *EPITHELIAL cells - Abstract
Studies the inhibitory effect of transforming growth factor-beta 1 on non-pathogenic gram-negative bacteria-induced nuclear factor-kappa beta recruitment to the interleukin-6 gene promoter in intestinal epithelial cells (IEC). Nuclear localization of phospho-RelA in IEC: Inhibition of histone acetylation.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.